Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial

Bora Gurel, M. Scott Lucia, Ian M. Thompson, Phyllis J. Goodman, Catherine M. Tangen, Alan R. Kristal, Howard L. Parnes, Ashraful Hoque, Scott M. Lippman, Siobhan Sutcliffe, Sarah B. Peskoe, Charles G. Drake, William G Nelson, Angelo Michael Demarzo, Elizabeth A Platz

Research output: Contribution to journalArticle

Abstract

Background: Chronic inflammation is hypothesized to influence prostate cancer development, although a definitive link has not been established. Methods: Prostate cancer cases (N = 191) detected on a for-cause (clinically indicated) or end-of-study (protocol directed) biopsy, and frequency-matched controls (N=209), defined as negative for cancer on an endof- study biopsy, were sampled from the placebo arm of the Prostate Cancer Prevention Trial. Inflammation prevalence and extent in benign areas of biopsy cores were visually assessed using digital images of hematoxylin and eosin-stained sections. Logistic regression was used to estimate associations. Results: Of note, 86.2% of cases and 78.2% of controls had at least one biopsy core (of three assessed) with inflammation in benign areas, most of which was chronic. Men who had at least one biopsy core with inflammation had 1.78 [95% confidence interval (CI), 1.04-3.06] times the odds of prostate cancer compared with men who had zero cores with inflammation. The association was stronger for high-grade disease (Gleason sum 7-10, N = 94; OR, 2.24; 95% CI, 1.06-4.71). These patterns were present when restricting to cases and controls in whom intraprostatic inflammation was the least likely to have influenced biopsy recommendation because their prostate-specific antigen (PSA) was low (

Original languageEnglish (US)
Pages (from-to)847-856
Number of pages10
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Prostate
Prostatic Neoplasms
Placebos
Inflammation
Biopsy
Confidence Intervals
Hematoxylin
Eosine Yellowish-(YS)
Prostate-Specific Antigen
Logistic Models
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Medicine(all)

Cite this

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. / Gurel, Bora; Lucia, M. Scott; Thompson, Ian M.; Goodman, Phyllis J.; Tangen, Catherine M.; Kristal, Alan R.; Parnes, Howard L.; Hoque, Ashraful; Lippman, Scott M.; Sutcliffe, Siobhan; Peskoe, Sarah B.; Drake, Charles G.; Nelson, William G; Demarzo, Angelo Michael; Platz, Elizabeth A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 23, No. 5, 2014, p. 847-856.

Research output: Contribution to journalArticle

Gurel, Bora ; Lucia, M. Scott ; Thompson, Ian M. ; Goodman, Phyllis J. ; Tangen, Catherine M. ; Kristal, Alan R. ; Parnes, Howard L. ; Hoque, Ashraful ; Lippman, Scott M. ; Sutcliffe, Siobhan ; Peskoe, Sarah B. ; Drake, Charles G. ; Nelson, William G ; Demarzo, Angelo Michael ; Platz, Elizabeth A. / Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. In: Cancer Epidemiology Biomarkers and Prevention. 2014 ; Vol. 23, No. 5. pp. 847-856.
@article{f40ff426a38545a8b2dc8175367eab5a,
title = "Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial",
abstract = "Background: Chronic inflammation is hypothesized to influence prostate cancer development, although a definitive link has not been established. Methods: Prostate cancer cases (N = 191) detected on a for-cause (clinically indicated) or end-of-study (protocol directed) biopsy, and frequency-matched controls (N=209), defined as negative for cancer on an endof- study biopsy, were sampled from the placebo arm of the Prostate Cancer Prevention Trial. Inflammation prevalence and extent in benign areas of biopsy cores were visually assessed using digital images of hematoxylin and eosin-stained sections. Logistic regression was used to estimate associations. Results: Of note, 86.2{\%} of cases and 78.2{\%} of controls had at least one biopsy core (of three assessed) with inflammation in benign areas, most of which was chronic. Men who had at least one biopsy core with inflammation had 1.78 [95{\%} confidence interval (CI), 1.04-3.06] times the odds of prostate cancer compared with men who had zero cores with inflammation. The association was stronger for high-grade disease (Gleason sum 7-10, N = 94; OR, 2.24; 95{\%} CI, 1.06-4.71). These patterns were present when restricting to cases and controls in whom intraprostatic inflammation was the least likely to have influenced biopsy recommendation because their prostate-specific antigen (PSA) was low (",
author = "Bora Gurel and Lucia, {M. Scott} and Thompson, {Ian M.} and Goodman, {Phyllis J.} and Tangen, {Catherine M.} and Kristal, {Alan R.} and Parnes, {Howard L.} and Ashraful Hoque and Lippman, {Scott M.} and Siobhan Sutcliffe and Peskoe, {Sarah B.} and Drake, {Charles G.} and Nelson, {William G} and Demarzo, {Angelo Michael} and Platz, {Elizabeth A}",
year = "2014",
doi = "10.1158/1055-9965.EPI-13-1126",
language = "English (US)",
volume = "23",
pages = "847--856",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial

AU - Gurel, Bora

AU - Lucia, M. Scott

AU - Thompson, Ian M.

AU - Goodman, Phyllis J.

AU - Tangen, Catherine M.

AU - Kristal, Alan R.

AU - Parnes, Howard L.

AU - Hoque, Ashraful

AU - Lippman, Scott M.

AU - Sutcliffe, Siobhan

AU - Peskoe, Sarah B.

AU - Drake, Charles G.

AU - Nelson, William G

AU - Demarzo, Angelo Michael

AU - Platz, Elizabeth A

PY - 2014

Y1 - 2014

N2 - Background: Chronic inflammation is hypothesized to influence prostate cancer development, although a definitive link has not been established. Methods: Prostate cancer cases (N = 191) detected on a for-cause (clinically indicated) or end-of-study (protocol directed) biopsy, and frequency-matched controls (N=209), defined as negative for cancer on an endof- study biopsy, were sampled from the placebo arm of the Prostate Cancer Prevention Trial. Inflammation prevalence and extent in benign areas of biopsy cores were visually assessed using digital images of hematoxylin and eosin-stained sections. Logistic regression was used to estimate associations. Results: Of note, 86.2% of cases and 78.2% of controls had at least one biopsy core (of three assessed) with inflammation in benign areas, most of which was chronic. Men who had at least one biopsy core with inflammation had 1.78 [95% confidence interval (CI), 1.04-3.06] times the odds of prostate cancer compared with men who had zero cores with inflammation. The association was stronger for high-grade disease (Gleason sum 7-10, N = 94; OR, 2.24; 95% CI, 1.06-4.71). These patterns were present when restricting to cases and controls in whom intraprostatic inflammation was the least likely to have influenced biopsy recommendation because their prostate-specific antigen (PSA) was low (

AB - Background: Chronic inflammation is hypothesized to influence prostate cancer development, although a definitive link has not been established. Methods: Prostate cancer cases (N = 191) detected on a for-cause (clinically indicated) or end-of-study (protocol directed) biopsy, and frequency-matched controls (N=209), defined as negative for cancer on an endof- study biopsy, were sampled from the placebo arm of the Prostate Cancer Prevention Trial. Inflammation prevalence and extent in benign areas of biopsy cores were visually assessed using digital images of hematoxylin and eosin-stained sections. Logistic regression was used to estimate associations. Results: Of note, 86.2% of cases and 78.2% of controls had at least one biopsy core (of three assessed) with inflammation in benign areas, most of which was chronic. Men who had at least one biopsy core with inflammation had 1.78 [95% confidence interval (CI), 1.04-3.06] times the odds of prostate cancer compared with men who had zero cores with inflammation. The association was stronger for high-grade disease (Gleason sum 7-10, N = 94; OR, 2.24; 95% CI, 1.06-4.71). These patterns were present when restricting to cases and controls in whom intraprostatic inflammation was the least likely to have influenced biopsy recommendation because their prostate-specific antigen (PSA) was low (

UR - http://www.scopus.com/inward/record.url?scp=84899746407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899746407&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-13-1126

DO - 10.1158/1055-9965.EPI-13-1126

M3 - Article

VL - 23

SP - 847

EP - 856

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 5

ER -